Epigenetic regulation in human cancer: the potential role of epi-drug in cancer therapy

[1]  Ni Zeng,et al.  LncRNA FAM83H-AS1 promotes triple-negative breast cancer progression by regulating the miR-136-5p/metadherin axis , 2020, Aging.

[2]  C. Brennan,et al.  LY6K Promotes Glioblastoma Tumorigenicity via CAV-1-Mediated ERK1/2 Signaling Enhancement. , 2020, Neuro-oncology.

[3]  Wei Wang,et al.  The EGFR-ZNF263 signaling axis silences SIX3 in glioblastoma epigenetically , 2020, Oncogene.

[4]  T. Boettger,et al.  RASSF10 is frequently epigenetically inactivated in kidney cancer and its knockout promotes neoplasia in cancer prone mice , 2020, Oncogene.

[5]  Z. Zeng,et al.  Emerging role of tumor-related functional peptides encoded by lncRNA and circRNA , 2020, Molecular Cancer.

[6]  Duan Ma,et al.  SLC34A2 simultaneously promotes papillary thyroid carcinoma growth and invasion through distinct mechanisms , 2020, Oncogene.

[7]  Jae Cheol Lee,et al.  Tumor-derived exosomal miR-619-5p promotes tumor angiogenesis and metastasis through the inhibition of RCAN1.4. , 2020, Cancer letters.

[8]  V. Lazar,et al.  A Comprehensive Picture of Extracellular Vesicles and Their Contents. Molecular Transfer to Cancer Cells , 2020, Cancers.

[9]  Tianxin Lin,et al.  circRNA circFUT8 Upregulates Krüpple-like Factor 10 to Inhibit the Metastasis of Bladder Cancer via Sponging miR-570-3p , 2020, Molecular therapy oncolytics.

[10]  M. Reese,et al.  Potential of Exosomal microRNA-200b as Liquid Biopsy Marker in Pancreatic Ductal Adenocarcinoma , 2020, Cancers.

[11]  N. Wong,et al.  Genomic and Epigenomic Features of Primary and Recurrent Hepatocellular Carcinomas. , 2019, Gastroenterology.

[12]  B. Baradaran,et al.  microRNA-181 serves as a dual-role regulator in the development of human cancers. , 2019, Free radical biology & medicine.

[13]  E. Blanco,et al.  The Bivalent Genome: Characterization, Structure, and Regulation. , 2019, Trends in genetics : TIG.

[14]  E. Filippi-Chiela,et al.  Tumor propagating cells: drivers of tumor plasticity, heterogeneity, and recurrence , 2019, Oncogene.

[15]  G. Calin,et al.  Current concepts of non-coding RNA regulation of immune checkpoints in cancer. , 2019, Molecular aspects of medicine.

[16]  Xiaofan Ding,et al.  Genomic and Epigenomic Features of Primary and Recurrent Hepatocellular Carcinomas. , 2019, Gastroenterology.

[17]  Xin Zhang,et al.  RBBP6, a RING finger-domain E3 ubiquitin ligase, induces epithelial–mesenchymal transition and promotes metastasis of colorectal cancer , 2019, Cell Death & Disease.

[18]  F. Ay,et al.  NSD2 overexpression drives clustered chromatin and transcriptional changes in a subset of insulated domains , 2019, Nature Communications.

[19]  Yong Li,et al.  Exosomes in Cancer Radioresistance , 2019, Front. Oncol..

[20]  P. Porcu,et al.  Preclinical Targeting of MicroRNA-214 in Cutaneous T-Cell Lymphoma. , 2019, The Journal of investigative dermatology.

[21]  Zu-hua Gao,et al.  Colorectal cancer-derived extracellular vesicles induce transformation of fibroblasts into colon carcinoma cells , 2019, Journal of Experimental & Clinical Cancer Research.

[22]  Xiaoyu Chen,et al.  The role of m6A RNA methylation in human cancer , 2019, Molecular cancer.

[23]  J. Kocerha,et al.  The Potential for microRNA Therapeutics and Clinical Research , 2019, Front. Genet..

[24]  Hanno Meyer,et al.  Resolving the controls of water vapour isotopes in the Atlantic sector , 2019, Nature Communications.

[25]  T. Guo,et al.  The histone H3 Lys 27 demethylase KDM6B promotes migration and invasion of glioma cells partly by regulating the expression of SNAI1 , 2019, Neurochemistry International.

[26]  N. Senzer,et al.  Bromodomain and extra-terminal motif inhibitors: a review of preclinical and clinical advances in cancer therapy , 2019, Future science OA.

[27]  L. Weiner,et al.  Targeting Multiple Receptors to Increase Checkpoint Blockade Efficacy , 2019, International journal of molecular sciences.

[28]  Jianjun Chen,et al.  IGF2BP1 promotes SRF-dependent transcription in cancer in a m6A- and miRNA-dependent manner , 2018, Nucleic acids research.

[29]  Shicheng Guo,et al.  Epigenetic silencing of ZNF132 mediated by methylation-sensitive Sp1 binding promotes cancer progression in esophageal squamous cell carcinoma , 2018, Cell Death & Disease.

[30]  V. Trochon-Joseph,et al.  Enhanced anti-tumor efficacy of checkpoint inhibitors in combination with the histone deacetylase inhibitor Belinostat in a murine hepatocellular carcinoma model , 2018, Cancer Immunology, Immunotherapy.

[31]  Yan Ding,et al.  Cancer-derived exosomal miR-25-3p promotes pre-metastatic niche formation by inducing vascular permeability and angiogenesis , 2018, Nature Communications.

[32]  A. Ciarrocchi,et al.  BRD4 and Cancer: going beyond transcriptional regulation , 2018, Molecular Cancer.

[33]  C. Elmets,et al.  Mogamulizumab versus vorinostat in previously treated cutaneous T-cell lymphoma (MAVORIC): an international, open-label, randomised, controlled phase 3 trial. , 2018, The Lancet. Oncology.

[34]  H. Wood.  FDA approves patisiran to treat hereditary transthyretin amyloidosis , 2018, Nature Reviews Neurology.

[35]  S. M. Toor,et al.  DNA methylation and repressive histones in the promoters of PD-1, CTLA-4, TIM-3, LAG-3, TIGIT, PD-L1, and galectin-9 genes in human colorectal cancer , 2018, Clinical Epigenetics.

[36]  Hao Qu,et al.  Epigenetic Regulation of CXCL12 Plays a Critical Role in Mediating Tumor Progression and the Immune Response In Osteosarcoma. , 2018, Cancer research.

[37]  G. Freeman,et al.  LSD1 Ablation Stimulates Anti-tumor Immunity and Enables Checkpoint Blockade , 2018, Cell.

[38]  B. Ali,et al.  DNA methylation and repressive H3K9 and H3K27 trimethylation in the promoter regions of PD-1, CTLA-4, TIM-3, LAG-3, TIGIT, and PD-L1 genes in human primary breast cancer , 2018, Clinical Epigenetics.

[39]  Yiping Li,et al.  DNA methyltransferase 3A isoform b contributes to repressing E-cadherin through cooperation of DNA methylation and H3K27/H3K9 methylation in EMT-related metastasis of gastric cancer , 2018, Oncogene.

[40]  B. V. Van Ness,et al.  EZH2 inhibitors sensitize myeloma cell lines to panobinostat resulting in unique combinatorial transcriptomic changes , 2018, Oncotarget.

[41]  S. Kubota,et al.  Zebularine exerts its antiproliferative activity through S phase delay and cell death in human malignant mesothelioma cells , 2018, Bioscience, biotechnology, and biochemistry.

[42]  P. Ma,et al.  Multiple functions of m6A RNA methylation in cancer , 2018, Journal of Hematology & Oncology.

[43]  Y. Lou,et al.  Next generation of immune checkpoint therapy in cancer: new developments and challenges , 2018, Journal of Hematology & Oncology.

[44]  D. Spector,et al.  Therapeutic Targeting of Long Non-Coding RNAs in Cancer. , 2018, Trends in molecular medicine.

[45]  W. Béguelin,et al.  Enhancer of zeste homolog 2 (EZH2) inhibitors , 2018, Leukemia & lymphoma.

[46]  C. Zahnow,et al.  DNA methyltransferase inhibition upregulates MHC-I to potentiate cytotoxic T lymphocyte responses in breast cancer , 2018, Nature Communications.

[47]  H. Döhner,et al.  Azacitidine improves clinical outcomes in older patients with acute myeloid leukaemia with myelodysplasia-related changes compared with conventional care regimens , 2017, BMC Cancer.

[48]  Samie R Jaffrey,et al.  Rethinking m6A Readers, Writers, and Erasers. , 2017, Annual review of cell and developmental biology.

[49]  D. Bailey,et al.  Safety and activity of microRNA-loaded minicells in patients with recurrent malignant pleural mesothelioma: a first-in-man, phase 1, open-label, dose-escalation study. , 2017, The Lancet. Oncology.

[50]  S. K. Zaidi,et al.  Bivalent Epigenetic Control of Oncofetal Gene Expression in Cancer , 2017, Molecular and Cellular Biology.

[51]  G. Castellani,et al.  RUNX2 expression in thyroid and breast cancer requires the cooperation of three non-redundant enhancers under the control of BRD4 and c-JUN , 2017, Nucleic acids research.

[52]  E. Thiel,et al.  Loss-of-function but not dominant-negative intragenic IKZF1 deletions are associated with an adverse prognosis in adult BCR-ABL-negative acute lymphoblastic leukemia , 2017, Haematologica.

[53]  Paul G. Thomas,et al.  De Novo Epigenetic Programs Inhibit PD-1 Blockade-Mediated T Cell Rejuvenation , 2017, Cell.

[54]  Elizabeth T. Wiles,et al.  H3K27 methylation: a promiscuous repressive chromatin mark. , 2017, Current opinion in genetics & development.

[55]  M. D’Incalci,et al.  The bromodomain inhibitor OTX015 (MK-8628) exerts anti-tumor activity in triple-negative breast cancer models as single agent and in combination with everolimus , 2016, Oncotarget.

[56]  Nathan Archer,et al.  m6A potentiates Sxl alternative pre-mRNA splicing for robust Drosophila sex determination , 2016, Nature.

[57]  H. Einsele,et al.  The Role of Panobinostat Plus Bortezomib and Dexamethasone in Treating Relapsed or Relapsed and Refractory Multiple Myeloma: A European Perspective , 2016, Advances in Therapy.

[58]  Benjamin G. Bitler,et al.  BET Bromodomain Inhibition Promotes Anti-tumor Immunity by Suppressing PD-L1 Expression. , 2016, Cell reports.

[59]  Bryan J. Venters,et al.  High-Resolution Mapping of RNA Polymerases Identifies Mechanisms of Sensitivity and Resistance to BET Inhibitors in t(8;21) AML. , 2016, Cell reports.

[60]  G. Gerken,et al.  Resminostat plus sorafenib as second-line therapy of advanced hepatocellular carcinoma - The SHELTER study. , 2016, Journal of hepatology.

[61]  S. Gupta,et al.  Reversible lysine-specific demethylase 1 antagonist HCI-2509 inhibits growth and decreases c-MYC in castration- and docetaxel-resistant prostate cancer cells , 2016, Prostate Cancer and Prostatic Diseases.

[62]  T. Preiss,et al.  METTL3 Gains R/W Access to the Epitranscriptome. , 2016, Molecular cell.

[63]  H. Dombret,et al.  Bromodomain inhibitor OTX015 in patients with acute leukaemia: a dose-escalation, phase 1 study. , 2016, The Lancet. Haematology.

[64]  G. Stein,et al.  Oncofetal Epigenetic Bivalency in Breast Cancer Cells: H3K4 and H3K27 Tri‐Methylation as a Biomarker for Phenotypic Plasticity , 2016, Journal of cellular physiology.

[65]  Min Gyu Lee,et al.  An essential role for UTX in resolution and activation of bivalent promoters , 2016, Nucleic acids research.

[66]  J. Bradner,et al.  The Bromodomain Inhibitor JQ1 and the Histone Deacetylase Inhibitor Panobinostat Synergistically Reduce N-Myc Expression and Induce Anticancer Effects , 2016, Clinical Cancer Research.

[67]  Arne Klungland,et al.  A majority of m6A residues are in the last exons, allowing the potential for 3′ UTR regulation , 2015, Genes & development.

[68]  Łukasz M. Boryń,et al.  Transcriptional plasticity promotes primary and acquired resistance to BET inhibition , 2015, Nature.

[69]  Kathleen R. Cho,et al.  Epigenetic silencing of Th1 type chemokines shapes tumor immunity and immunotherapy , 2015, Nature.

[70]  L. Ouafik,et al.  Abstract 2625: Targeting prostate cancer stem cells (CSCs) with the novel BET bromodomain (BRD) protein inhibitor OTX015 , 2015 .

[71]  G. Wang,et al.  Targeting EZH2 and PRC2 dependence as novel anticancer therapy. , 2015, Experimental hematology.

[72]  M. Dimopoulos,et al.  Panobinostat: a novel pan-deacetylase inhibitor for the treatment of relapsed or relapsed and refractory multiple myeloma , 2015, Expert review of anticancer therapy.

[73]  Manel Esteller,et al.  RNA-RNA interactions in gene regulation: the coding and noncoding players. , 2015, Trends in biochemical sciences.

[74]  S. Tavazoie,et al.  N6-methyladenosine marks primary microRNAs for processing , 2015, Nature.

[75]  O. Bernard,et al.  TET proteins and the control of cytosine demethylation in cancer , 2015, Genome Medicine.

[76]  Xiuheng Liu,et al.  Relationship between LSD1 expression and E-cadherin expression in prostate cancer , 2015, International Urology and Nephrology.

[77]  Karim Benkirane,et al.  Comparison of DNA methylation profiles in human fetal and adult red blood cell progenitors , 2015, Genome Medicine.

[78]  Takayoshi Suzuki,et al.  NCL1, a highly selective lysine-specific demethylase 1 inhibitor, suppresses prostate cancer without adverse effect , 2014, Oncotarget.

[79]  R. Weinberg,et al.  How does multistep tumorigenesis really proceed? , 2015, Cancer discovery.

[80]  L. van Doorn,et al.  In Vitro Antiviral Activity and Preclinical and Clinical Resistance Profile of Miravirsen, a Novel Anti-Hepatitis C Virus Therapeutic Targeting the Human Factor miR-122 , 2014, Antimicrobial Agents and Chemotherapy.

[81]  M. Aftab,et al.  Long noncoding RNAs as putative biomarkers for prostate cancer detection. , 2014, The Journal of molecular diagnostics : JMD.

[82]  L. Chung,et al.  Stromal fibroblast-derived miR-409 promotes epithelial-to-mesenchymal transition and prostate tumorigenesis , 2014, Oncogene.

[83]  Schraga Schwartz,et al.  Perturbation of m6A writers reveals two distinct classes of mRNA methylation at internal and 5' sites. , 2014, Cell reports.

[84]  David A. Drew,et al.  Loss of the polycomb mark from bivalent promoters leads to activation of cancer-promoting genes in colorectal tumors. , 2014, Cancer research.

[85]  M. Hollingshead,et al.  Novel DNA methyltransferase-1 (DNMT1) depleting anticancer nucleosides, 4′-thio-2′-deoxycytidine and 5-aza-4′-thio-2′-deoxycytidine , 2014, Cancer Chemotherapy and Pharmacology.

[86]  S. Baylin,et al.  Cancer epigenetics: tumor heterogeneity, plasticity of stem-like states, and drug resistance. , 2014, Molecular cell.

[87]  A. Jimeno,et al.  Belinostat for the treatment of peripheral T-cell lymphomas. , 2014, Drugs of today.

[88]  N. Sharpless,et al.  Detecting and characterizing circular RNAs , 2014, Nature Biotechnology.

[89]  Samir Adhikari,et al.  Mammalian WTAP is a regulatory subunit of the RNA N6-methyladenosine methyltransferase , 2014, Cell Research.

[90]  Miao Yu,et al.  A METTL3-METTL14 complex mediates mammalian nuclear RNA N6-adenosine methylation , 2013, Nature chemical biology.

[91]  H. Kantarjian,et al.  Multivariate and subgroup analyses of a randomized, multinational, phase 3 trial of decitabine vs treatment choice of supportive care or cytarabine in older patients with newly diagnosed acute myeloid leukemia and poor- or intermediate-risk cytogenetics , 2014, BMC Cancer.

[92]  J. Issa,et al.  Architecture of epigenetic reprogramming following Twist1-mediated epithelial-mesenchymal transition , 2013, Genome Biology.

[93]  R. Johnstone,et al.  An intact immune system is required for the anticancer activities of histone deacetylase inhibitors. , 2013, Cancer research.

[94]  G. Ganji,et al.  BET Inhibition Silences Expression of MYCN and BCL2 and Induces Cytotoxicity in Neuroblastoma Tumor Models , 2013, PloS one.

[95]  Hongbo Zhao,et al.  Tet family of 5-methylcytosine dioxygenases in mammalian development , 2013, Journal of Human Genetics.

[96]  Bohuslav Melichar,et al.  Randomized phase II, double-blind, placebo-controlled study of exemestane with or without entinostat in postmenopausal women with locally recurrent or metastatic estrogen receptor-positive breast cancer progressing on treatment with a nonsteroidal aromatase inhibitor. , 2013, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[97]  Tim J. Wigle,et al.  Durable tumor regression in genetically altered malignant rhabdoid tumors by inhibition of methyltransferase EZH2 , 2013, Proceedings of the National Academy of Sciences.

[98]  David A. Orlando,et al.  Selective Inhibition of Tumor Oncogenes by Disruption of Super-Enhancers , 2013, Cell.

[99]  D. Spector,et al.  The noncoding RNA MALAT1 is a critical regulator of the metastasis phenotype of lung cancer cells. , 2013, Cancer research.

[100]  Arne Klungland,et al.  ALKBH5 is a mammalian RNA demethylase that impacts RNA metabolism and mouse fertility. , 2013, Molecular cell.

[101]  W. Zhou,et al.  The DNA methyltransferase inhibitor zebularine induces mitochondria-mediated apoptosis in gastric cancer cells in vitro and in vivo. , 2013, Biochemical and biophysical research communications.

[102]  Giacomo Cavalli.  EZH2 Goes Solo , 2012, Science.

[103]  J. Whetstine,et al.  Histone lysine methylation dynamics: establishment, regulation, and biological impact. , 2012, Molecular cell.

[104]  H. Varmus,et al.  Sensitivity of human lung adenocarcinoma cell lines to targeted inhibition of BET epigenetic signaling proteins , 2012, Proceedings of the National Academy of Sciences.

[105]  Christopher J. Ott,et al.  BET bromodomain inhibition targets both c-Myc and IL7R in high-risk acute lymphoblastic leukemia. , 2012, Blood.

[106]  Robert Brown,et al.  Candidate DNA methylation drivers of acquired cisplatin resistance in ovarian cancer identified by methylome and expression profiling , 2012, Oncogene.

[107]  H. Manev,et al.  Effect of valproic acid on mitochondrial epigenetics. , 2012, European journal of pharmacology.

[108]  Z. Estrov,et al.  Therapy with the histone deacetylase inhibitor pracinostat for patients with myelofibrosis. , 2012, Leukemia research.

[109]  Nadav S. Bar,et al.  Landscape of transcription in human cells , 2012, Nature.

[110]  M. Ahn,et al.  Randomized phase II trial of first-line treatment with pemetrexed-cisplatin, followed sequentially by gefitinib or pemetrexed, in East Asian, never-smoker patients with advanced non-small cell lung cancer. , 2012, Lung cancer.

[111]  O. Elemento,et al.  Comprehensive Analysis of mRNA Methylation Reveals Enrichment in 3′ UTRs and near Stop Codons , 2012, Cell.

[112]  S. Friedman,et al.  Combination therapy for hepatocellular carcinoma: additive preclinical efficacy of the HDAC inhibitor panobinostat with sorafenib. , 2012, Journal of hepatology.

[113]  F. Hirsch,et al.  Randomized phase II trial of erlotinib with and without entinostat in patients with advanced non-small-cell lung cancer who progressed on prior chemotherapy. , 2012, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[114]  S. Bates,et al.  Romidepsin: a new drug for the treatment of cutaneous T-cell lymphoma. , 2012, Clinical journal of oncology nursing.

[115]  J. Finsterer,et al.  Mitochondrial toxicity of antiepileptic drugs and their tolerability in mitochondrial disorders , 2012, Expert opinion on drug metabolism & toxicology.

[116]  A. Ferrando,et al.  Genetic Inactivation of the PRC2 Complex in T-Cell Acute Lymphoblastic Leukemia , 2011, Nature Medicine.

[117]  M. Esteller,et al.  Dynamic epigenetic regulation of the microRNA-200 family mediates epithelial and mesenchymal transitions in human tumorigenesis , 2011, Oncogene.

[118]  E. Buckles,et al.  Aberrant DNA Methylation and Prostate Cancer , 2011, Current genomics.

[119]  Chengqi Yi,et al.  N6-Methyladenosine in Nuclear RNA is a Major Substrate of the Obesity-Associated FTO , 2011, Nature chemical biology.

[120]  J. Hainsworth,et al.  A Phase II Trial of Panobinostat, a Histone Deacetylase Inhibitor, in the Treatment of Patients with Refractory Metastatic Renal Cell Carcinoma , 2011, Cancer investigation.

[121]  G. Giaccone,et al.  Phase II study of belinostat in patients with recurrent or refractory advanced thymic epithelial tumors. , 2011, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[122]  Jørgen Kjems,et al.  Coordinated epigenetic repression of the miR‐200 family and miR‐205 in invasive bladder cancer , 2011, International journal of cancer.

[123]  A. Chase,et al.  Aberrations of EZH2 in Cancer , 2011, Clinical Cancer Research.

[124]  O. Elemento,et al.  EZH2-mediated epigenetic silencing in germinal center B cells contributes to proliferation and lymphomagenesis. , 2010, Blood.

[125]  Peter A. Jones,et al.  Targeting DNA methylation for epigenetic therapy. , 2010, Trends in pharmacological sciences.

[126]  Xiong Cai,et al.  CUDC-101, a multitargeted inhibitor of histone deacetylase, epidermal growth factor receptor, and human epidermal growth factor receptor 2, exerts potent anticancer activity. , 2010, Cancer research.

[127]  H. Dombret,et al.  Phase 2 clinical trial of 5-azacitidine, valproic acid, and all-trans retinoic acid in patients with high-risk acute myeloid leukemia or myelodysplastic syndrome , 2010, Oncotarget.

[128]  Martha R. Stampfer,et al.  Role for DNA Methylation in the Regulation of miR-200c and miR-141 Expression in Normal and Cancer Cells , 2010, PloS one.

[129]  Kurt Zatloukal,et al.  Histone deacetylase inhibitor vorinostat suppresses the growth of uterine sarcomas in vitro and in vivo , 2010, Molecular Cancer.

[130]  Lee E. Edsall,et al.  Human DNA methylomes at base resolution show widespread epigenomic differences , 2009, Nature.

[131]  M. Schaefer,et al.  Azacytidine inhibits RNA methylation at DNMT2 target sites in human cancer cell lines. , 2009, Cancer research.

[132]  Quan-sheng Zhu,et al.  Combining PCI-24781, a Novel Histone Deacetylase Inhibitor, with Chemotherapy for the Treatment of Soft Tissue Sarcoma , 2009, Clinical Cancer Research.

[133]  L. Borsu,et al.  Histone deacetylases are required for androgen receptor function in hormone-sensitive and castrate-resistant prostate cancer. , 2009, Cancer research.

[134]  C. Burge,et al.  Most mammalian mRNAs are conserved targets of microRNAs. , 2008, Genome research.

[135]  K. Robertson,et al.  DNA methylation in development and human disease. , 2008, Mutation research.

[136]  Guo-Cheng Yuan,et al.  EZH1 mediates methylation on histone H3 lysine 27 and complements EZH2 in maintaining stem cell identity and executing pluripotency. , 2008, Molecular cell.

[137]  B. Ren,et al.  Role of the Histone H3 Lysine 4 Methyltransferase, SET7/9, in the Regulation of NF-κB-dependent Inflammatory Genes , 2008, Journal of Biological Chemistry.

[138]  F. Lyko,et al.  Modes of action of the DNA methyltransferase inhibitors azacytidine and decitabine , 2008, International journal of cancer.

[139]  G. Peters,et al.  CI-994 (N-acetyl-dinaline) in combination with conventional anti-cancer agents is effective against acute myeloid leukemia in vitro and in vivo. , 2008, Oncology reports.

[140]  G. Goodall,et al.  The miR-200 family and miR-205 regulate epithelial to mesenchymal transition by targeting ZEB1 and SIP1 , 2008, Nature Cell Biology.

[141]  Sun-Mi Park,et al.  The miR-200 family determines the epithelial phenotype of cancer cells by targeting the E-cadherin repressors ZEB1 and ZEB2. , 2008, Genes & development.

[142]  Qian Tao,et al.  DNA methyltransferase 3B (DNMT3B) mutations in ICF syndrome lead to altered epigenetic modifications and aberrant expression of genes regulating development, neurogenesis and immune function. , 2008, Human molecular genetics.

[143]  Stefan Offermanns,et al.  Encyclopedia of Molecular Pharmacology , 2008 .

[144]  R. Amato.  Inhibition of DNA methylation by antisense oligonucleotide MG98 as cancer therapy. , 2007, Clinical genitourinary cancer.

[145]  Richard Pazdur,et al.  FDA approval summary: vorinostat for treatment of advanced primary cutaneous T-cell lymphoma. , 2007, The oncologist.

[146]  S. Spivack,et al.  Overexpression of the microRNA hsa-miR-200c leads to reduced expression of transcription factor 8 and increased expression of E-cadherin. , 2007, Cancer research.

[147]  O. Politz,et al.  MS-275, a potent orally available inhibitor of histone deacetylases--the development of an anticancer agent. , 2007, The international journal of biochemistry & cell biology.

[148]  Adrian Bird,et al.  Perceptions of epigenetics , 2007, Nature.

[149]  Dustin E. Schones,et al.  High-Resolution Profiling of Histone Methylations in the Human Genome , 2007, Cell.

[150]  F. Lyko,et al.  Methylation of Human MicroRNA Genes in Normal and Neoplastic Cells , 2007, Cell cycle.

[151]  M. Szyf,et al.  Valproate induces widespread epigenetic reprogramming which involves demethylation of specific genes. , 2007, Carcinogenesis.

[152]  C. Pérez-Plasencia,et al.  A phase II study of epigenetic therapy with hydralazine and magnesium valproate to overcome chemotherapy resistance in refractory solid tumors , 2007, BMC Cancer.

[153]  F. Forneris,et al.  A Highly Specific Mechanism of Histone H3-K4 Recognition by Histone Demethylase LSD1* , 2006, Journal of Biological Chemistry.

[154]  Yi Zhang,et al.  JmjC-domain-containing proteins and histone demethylation , 2006, Nature Reviews Genetics.

[155]  Alessandra Marini,et al.  Epigenetic silencing of the PTEN gene in melanoma. , 2006, Cancer research.

[156]  Z. Cao,et al.  CRA-024781: a novel synthetic inhibitor of histone deacetylase enzymes with antitumor activity in vitro and in vivo , 2006, Molecular Cancer Therapeutics.

[157]  James A. Cuff,et al.  A Bivalent Chromatin Structure Marks Key Developmental Genes in Embryonic Stem Cells , 2006, Cell.

[158]  John M Bennett,et al.  Decitabine improves patient outcomes in myelodysplastic syndromes , 2006, Cancer.

[159]  R. Reinhardt,et al.  Accuracy of DNA methylation pattern preservation by the Dnmt1 methyltransferase , 2006, Nucleic acids research.

[160]  H. Erdjument-Bromage,et al.  Histone demethylation by a family of JmjC domain-containing proteins , 2006, Nature.

[161]  A. Mirmohammadsadegh,et al.  Epigenetic inactivation of tumor suppressor genes in serum of patients with cutaneous melanoma. , 2006, The Journal of investigative dermatology.

[162]  K. Robertson.  DNA methylation and human disease , 2005, Nature Reviews Genetics.

[163]  Alexander V. Lyubimov,et al.  Plasma Pharmacokinetics, Oral Bioavailability, and Interspecies Scaling of the DNA Methyltransferase Inhibitor, Zebularine , 2005, Clinical Cancer Research.

[164]  Gangning Liang,et al.  Preferential response of cancer cells to zebularine. , 2004, Cancer cell.

[165]  Peter A. Jones,et al.  Epigenetics in human disease and prospects for epigenetic therapy , 2004, Nature.

[166]  Peter A. Jones,et al.  Continuous Zebularine Treatment Effectively Sustains Demethylation in Human Bladder Cancer Cells , 2004, Molecular and Cellular Biology.

[167]  E. Eisenhauer,et al.  A phase I pharmacokinetic and pharmacodynamic study of the DNA methyltransferase 1 inhibitor MG98 administered twice weekly. , 2003, Annals of oncology : official journal of the European Society for Medical Oncology.

[168]  M. Grever,et al.  Identification of thiols and glutathione conjugates of depsipeptide FK228 (FR901228), a novel histone protein deacetylase inhibitor, in the blood. , 2003, Rapid communications in mass spectrometry : RCM.

[169]  V. Pirrotta,et al.  Drosophila Enhancer of Zeste/ESC Complexes Have a Histone H3 Methyltransferase Activity that Marks Chromosomal Polycomb Sites , 2002, Cell.

[170]  Brigitte Wild,et al.  Histone Methyltransferase Activity of a Drosophila Polycomb Group Repressor Complex , 2002, Cell.

[171]  Hengbin Wang,et al.  Role of Histone H3 Lysine 27 Methylation in Polycomb-Group Silencing , 2002, Science.

[172]  Minoru Yoshida,et al.  FK228 (depsipeptide) as a natural prodrug that inhibits class I histone deacetylases. , 2002, Cancer research.

[173]  Lei Zhou,et al.  Zebularine: a novel DNA methylation inhibitor that forms a covalent complex with DNA methyltransferases. , 2002, Journal of molecular biology.

[174]  Peter A. Jones,et al.  The fundamental role of epigenetic events in cancer , 2002, Nature Reviews Genetics.

[175]  J. Holland,et al.  Randomized controlled trial of azacitidine in patients with the myelodysplastic syndrome: a study of the cancer and leukemia group B. , 2002, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[176]  Gangning Liang,et al.  Cooperativity between DNA Methyltransferases in the Maintenance Methylation of Repetitive Elements , 2002, Molecular and Cellular Biology.

[177]  T. Mahmoudi,et al.  Chromatin silencing and activation by Polycomb and trithorax group proteins , 2001, Oncogene.

[178]  R. Jaenisch,et al.  Baculovirus-mediated expression and characterization of the full-length murine DNA methyltransferase. , 1997, Nucleic acids research.

[179]  S. Kato,et al.  Novel benzamides as selective and potent gastrokinetic agents. 2. Synthesis and structure-activity relationships of 4-amino-5-chloro-2-ethoxy-N-[[4-(4-fluorobenzyl)-2- morpholinyl]methyl] benzamide citrate (AS-4370) and related compounds. , 1991, Journal of medicinal chemistry.

[180]  A. Bird.  CpG-rich islands and the function of DNA methylation , 1986, Nature.

[181]  C. Waddington.  The evolution of an evolutionist , 1975 .